Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Early smoking cessation associated with higher survival rates following a lung cancer diagnosis

Quitting smoking early was associated with higher survival rates following a lung cancer diagnosis, according to a new study led by researchers at Harvard T.H. Chan School of Public Health.

5 May 2023

Spinal cord stimulation may help reduce chronic pain in people undergoing active cancer treatment

Researchers at Johns Hopkins University School of Medicine say they have evidence from a new study in rats that spinal cord stimulation (SCS) may be useful in reducing chronic pain in people undergoing active treatment with a common anti-cancer drug.

From Elekta 27 Apr 2023

ASTRO/ESTRO's clinical guideline offers recommendations on the use of local therapy for oligometastatic NSCLC

A new clinical guideline from the American Society for Radiation Oncology and European Society for Radiotherapy & Oncology provides guidance on the use of definitive local therapy-; including radiation and surgery-; to treat patients with oligometastatic non-small cell lung cancer (NSCLC).

25 Apr 2023

New approach to CAR T-cell therapy shows promise against small cell lung cancer in preclinical study

A new approach to chimeric antigen receptor T-cell (CAR T) therapy has shown great promise against small cell lung cancer (SCLC) in a preclinical study.

25 Apr 2023

Pre- and post-surgical immunotherapy-based treatment significantly improved lung cancer outcomes

A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to Phase III trial results presented today by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2023.

17 Apr 2023

Changes to tumor DNA can help predict cancer's next move

Knowing whether a tumor might grow or spread to other parts of a patient’s body could be key to survival – and now scientists are one step closer to unlocking the ability to predict just that.

13 Apr 2023

Cedars-Sinai Cancer collaborates on a streamlined clinical trial design in Pragmatica-Lung Study

Investigators from Cedars-Sinai Cancer are collaborating on a streamlined clinical trial design in a study called Pragmatica-Lung.

12 Apr 2023

Pragmatica-Lung Study aims to increase accessibility to cancer clinical trials

The National Cancer Institute, part of the National Institutes of Health (NIH), has helped launch a phase 3 randomized clinical trial (NCT05633602) of a two-drug combination to treat patients with advanced non-small cell lung cancer (NSCLC).

12 Apr 2023

Clinical trial may change the paradigm of care for patients with ALK-driven high-risk neuroblastoma

In a significant step for the treatment of neuroblastoma, an international group of researchers led by Children's Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University and the New Approaches to Neuroblastoma Therapy (NANT) Consortium has shown that the targeted therapy lorlatinib is safe and effective in treating high-risk neuroblastoma.

4 Apr 2023

TiY: Cancer diagnosis and treatment in a single step

Cancer is not incurable anymore. Nevertheless, according to statistics released by Statistics Korea last year, cancer remained the primary cause of mortality in Korea in 2021.

4 Apr 2023

Nuclear medicine brain imaging can help evaluate the biological changes that cause chemo-brain

A newly published literature review sheds light on how nuclear medicine brain imaging can help evaluate the biological changes that cause chemotherapy-related cognitive impairment (CRCI), commonly known as chemo-brain.

28 Mar 2023

Trial shows encouraging results for neoadjuvant dual immunotherapy and chemotherapy in patients with resectable NSCLC

In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical, combination of nivolumab plus platinum-based chemotherapy, resulted in a major pathologic response (MPR) in half of all treated patients with early-stage, resectable non-small cell lung cancer (NSCLC).

16 Mar 2023

Immunochemistry multiplex for solid tumor analytical validation

In this interview, NewsMedical exchanges with Cerba on how to use T-regulatory immunochemsitry multiplex for solid tumor analytical validation.

From Cerba Research 16 Mar 2023

One-Pot-LAMP: A promising tool for non-small cell lung cancer diagnosis

Researchers assessed the efficiency of a genetic decoding system for diagnosing non-small cell lung cancer (NSCLC).

16 Mar 2023

Scientists generate 3D ultra-resolution maps of mitochondrial networks in lung tumors

Scientists have long known that mitochondria, the "powerhouses" of cells, play a crucial role in the metabolism and energy production of cancer cells.

15 Mar 2023

Yale scientists seek to identify optimal sequential treatments for advanced cancer

A team of Yale scientists seeks to determine which treatment sequences produce the best results for people with advanced cancer while examining the cost of these treatments.

6 Mar 2023

Evaluating how bacterial therapeutics may synergize with existing anti-cancer therapies

It may come as a surprise, but bacteria love to grow inside tumors. It's the environment-;tumors are typically acidic, have low amounts of oxygen, and are filled with dead cells, which all facilitate bacterial growth.

6 Mar 2023

Neoadjuvant nivolumab treatment improves survival rates in NSCLC patients

Patients with resectable non-small cell lung cancer (NSCLC) who were treated with neoadjuvant nivolumab had improved five-year recurrence-free and overall survival rates compared with historical outcomes.

15 Feb 2023

MD Anderson announces licensing agreements with BostonGene and Tempus for its EGFR Classification

The University of Texas MD Anderson Cancer Center today announced licensing agreements with BostonGene Corporation and Tempus for the MD Anderson EGFR Classification, which groups EGFR mutations in non-small cell lung cancer (NSCLC) based on structural modifications and sensitivity to available therapies.

19 Jan 2023

Study finds wide variation in the quality of care for lung cancer across the U.S.

Treatment for lung cancer is rapidly evolving, with new technologies and research-proven procedures.

18 Jan 2023